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Abstract  
Ischemic stroke occurs under a variety of clinical conditions and has different 
pathogeneses, resulting in necrosis of brain parenchyma. Stroke pathogenesis is 
characterized by neuroinflammation and endothelial dysfunction. Some of the main 
processes triggered in the early stages of ischemic damage are the rapid activation of 
resident inflammatory cells (microglia, astrocytes and endothelial cells), inflammatory 
cytokines, and translocation of intercellular nuclear factors. Inflammation in stroke includes 
all the processes mentioned above, and it consists of either protective or detrimental 
effects concerning the “polarization” of these processes. This polarization comes out 
from the interaction of all the molecular pathways that regulate genome expression: the 
epigenetic factors. In recent years, new regulation mechanisms have been cleared, and 
these include non-coding RNAs, adenosine receptors, and the activity of mesenchymal 
stem/stromal cells and microglia. We reviewed how long non-coding RNA and microRNA 
have emerged as an essential mediator of some neurological diseases. We also clarified 
that their roles in cerebral ischemic injury may provide novel targets for the treatment 
of ischemic stroke. To date, we do not have adequate tools to control pathophysiological 
processes associated with stroke. Our goal is to review the role of non-coding RNAs and 
innate immune cells (such as microglia and mesenchymal stem/stromal cells) and the 
possible therapeutic effects of their modulation in patients with acute ischemic stroke. 
A better understanding of the mechanisms that influence the “polarization” of the 
inflammatory response after the acute event seems to be the way to change the natural 
history of the disease.
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Introduction 
Ischemic stroke encompasses a broad spectrum of clinical 
conditions, with different pathogenesis, leading to necrosis of 
brain parenchyma. The first hours after the vascular occlusion 
represent a crucial point that could significantly influence 
stroke patients’ prognosis by involving almost the entire 
repertoire of innate and adaptative immunity cells. These cells 
regulate the mechanisms of neural and glial cell apoptosis and 
regulate brain restoration processes (Anrather and Iadecola, 
2016). 
Inflammation and endothelial dysfunction play a vital role in 
ischemic stroke’s pathogenesis, especially in the first hours 
after ischemic injury (Tuttolomondo et al., 2020). Some of 
the main processes triggered in the early stages of ischemic 
damage are the rapid activation of resident inflammatory 
cells (microglia, astrocytes and endothelial cells), production 
of inflammatory mediators, and translocation of intercellular 
nuclear factors (Garcia-Bonilla et al., 2015; Gülke et al., 2018). 
These processes can lead to brain damage and amplification 
of cerebral inflammation, and they can also result in 
neuroplasticity, brain regeneration, and neurovascular 
remodelling. In recent years, several epigenetic factors have 
been related to the polarization of inflammatory processes. 
Neuroinflammation includes all the processes mentioned 
above. It exhibits either protective or detrimental effect on 
the “polarization” of these processes. This polarization comes 
out from the interaction of all the molecular pathways that 
regulate genome expression: the epigenetic factors.
One of the questions that researchers have been trying 
to answer in recent years is whether it would be possible 
to change the natural history of this disabling disease by 
identifying the genetic factors behind it.   
In recent years, new gene regulation mechanisms have been 
cleared, and these include non-coding RNAs (ncRNAs). Non-
coding RNAs are RNA molecules transcribed from the genome 
that do not encode proteins that play a big part in epigenetic 
regulation of gene expression in addition to their roles at the 
transcriptional and post-transcriptional level (Ning and Li, 
2018). This family includes microRNA (miRNA), intronic RNA, 
repetitive RNA and long non-coding RNA (lncRNA) (Table 1). 
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(AMP) degradation. High extracellular concentrations of 
adenosine can be considered a general harm signal that 
contributes to the recruitment of damage-associated 
molecular effectors. Adenosine action is mediated by four 
metabotropic receptors (G-protein coupled) called: A1, A2A, 
A2B, and A3 adenosine receptors (A1Rs, A2Ars, A2BRs, and 
A3Rs, respectively).
A2BR needs much higher adenosine concentrations (in the 
µM range) than A1Rs, A2Ars and A3Rs, for being activated, 
the clue is that these levels are reached only under conditions 
of tissue damage or injury (Coppi et al., 2020).
Recently, Colotta et al. (2012) showed that the selective block 
of A2BRs by the antagonist PSB-603 and by MRS1754 prevents 
irreversible synaptic failure after 7-minute oxygen and glucose 
deprivation event in the hippocampus and that anoxic 
depolarization is wholly abolished in A2BR antagonist-treated 
hippocampal slices exposed to 7-minute oxygen and glucose 
deprivation and is significantly delayed in slices undergoing 
a 30-minute oxygen and glucose deprivation insult. Some 
studies also tried to investigate the effects of modulating 
A2bR in endothelial damage. 
Eckle et al. (2008) demonstrated that there was an attenuate 
vascular leakage in mice ablated of A2BRs on bone marrow 
cells during hypoxia. However, other studies demonstrated 
that the same receptor’s activation is also neuroprotective in 
a different phase of brain ischemia. Li et al. (2017) showed 
that treatment with intravenous A2bR agonist (BAY60-6583) 
reduced lesion volume in the absence or presence of tPA and 
attenuated brain oedema, blood-brain barrier disruption, and 
tPA-exacerbated hemorrhagic transformation at 24 hours 
after ischemia induced by transient middle cerebral artery 
occlusion (tMCAo). 
These data suggest that stimulation of A2BR plays a dual 
time-related role after brain ischemia. In the early hours after 
ischemia, an increase in adenosine’s cerebral extracellular 
levels able to activate low-affinity A2BRs may contribute 
to expanding excitotoxicity. On the contrary, in the hours 
following ischemia, when neuroinflammation develops, 
A2BRs located on glial, vascular endothelial, and blood cells 
exert a principal immunomodulatory role attenuating the 
neuroinflammation (Coppi et al., 2020).
Possible Therapeutic Applications of Epigenetic 
Factors
Although stroke has represented and still represents a field of 
enormous scientific and clinical interest due to its significant 
prevalence and mortality, therapeutic strategies are still 
limited to date. The only drugs significantly associated with a 
reduction in morbidity, mortality, and sequelae, and therefore 
recommended in the specific scientific society’s principal 
guidelines, are thrombolytic factors (with a strict therapeutic 
window) and some antiplatelet drugs (Powers et al., 2019).   
Full understanding of the regulatory networks linked to 
inflammation in the first minutes/hours after the ischemic 
event represents a new direction for stroke research, 
but which is the state-of-art and the clinical therapeutic 
implication of these findings? Are we really close to 
understanding these mechanisms and transforming this 
knowledge into therapeutic approaches that affect our 
patients’ outcome?
To date,  we do not have adequate tools  to control 
pathophysiological processes associated with stroke. Thus, 
the microRNAs have to be considered as a very promising 
target for future stroke therapies, and there is a growing 
body of evidences that miRNA-based therapies hold great 
promise. Nevertheless, despite their potential, which has 
been documented for several years now, several significant 
limitations are related to finding factors that can bind their 
miRNA targets. Other related limitations include in vivo 
stability, limited tissue distribution, and untoward side effects. 
Administration of miRNAs in the absence of a specific and 
stable carrier presents limited tissue distribution, and these 
miRNAs are fast metabolized by the liver and kidney and 
rapidly excreted in the urine. Besides, the lethal dosage (LD50) 
of specific miRNAs has yet to be recognized.
As shown before, in early stages following ischemic damage, 
there is an increase in the expression of a large number 
of microRNAs. These miRNAs can lead on one hand to an 
expression of different protective genes, or on the other hand 
to an increase in the transcription of genes that stimulate 
inflammatory processes. Thereby, inhibition of these miRNAs 
may be a therapeutic target for ischemic stroke (Li et al., 2020).
One of the first-studied methods to decrease miRNA level is 
the utilization of complementary sequences of nucleotide 
(anti-sense oligonucleotide) binding to the mature miRNA and 
blocking miRNA activity. These molecules are called antagomir, 
and their usage could be a useful approach to inhibit miRNA 
function. Therefore, an antagomir may be another therapeutic 
option when upregulated miRNAs are pathogenic (Zhang et 
al., 2013a). 
Antagomirs’ advantage is that they can be delivered into cells 
directly without any vector assistant, considering that they 
are nuclease resistant, which avoids the complication of using 
delivery vehicles. However, although antagomirs could easily 
be delivered intravenously, there is poor brain distribution due 
to the blood-brain barrier, which prevents most exogenous 
substances from entering the CNS. The drawbacks that limit 
antagomirs application as therapeutic reagents in humans 
are the need for high doses and their possible side effects 
(Krützfeldt et al., 2005).
Contrariwise antagomirs, gain-of-function for a specific miRNA 
can be achieved by overexpressing a specific protective 
miRNA’s mature sequence. miRNA mimics are molecules that 
can be chemically synthesized as oligonucleotides according 
to sequences of the endogenous miRNA. Double-stranded 
miRNA mimics, with the sequence of one strand identical to 
the endogenous mature miRNA, are usually used to increase 
the efficiency of augmenting miRNA expression (Wang, 2011). 
However, the effectiveness of miRNA mimics is low, especially 
in neurons, and the transfection is usually transient, which has 
limited its application.
Other studied approaches that could overcome these 
challenges are related to the utilization of either viral vectors 
or non-viral delivery systems such as liposomes. However, both 
liposomes and viral vectors may be toxic or immunogenic, 
restricting their clinical application. Liposomes are utilized to 
deliver small interference RNAs, a family of double-stranded 
RNA molecules that plays a role in post-transcriptional gene 
silencing. However, synthetic systems such as liposomes have 
relatively lower yield compared to viral vectors (Zhang et al, 
2013b).
miRNAs administration has also been evaluated by the 
utilization of mechanical methods such as high-pressure 
injection and electroporation. Still, these methods are linked 
to significant damage to the tissues (Kishida et al., 2004). 
Although MSC-derived extracellular vesicle therapeutics is 
still at an early stage, research is rapidly increasing and is 
demonstrating a promising approach for patients with severe 
stroke (Bang and Kim, 2019). 
Despite their recent introduction, MSC therapies have already 
been tested in preclinical studies and clinical trials, and 
extracellular vesicle-mediated therapy has shown advantages 
over other cell therapies in stroke patients, in terms of 
biodistribution, because of the ability to cross the blood-brain 
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Non-coding RNAs 
lncRNAs, with lengths exceeding 200 nucleotides, have critical 
functions in various disorders. The lncRNAs are shown to 
develop angiogenesis, cell apoptosis, inflammation, and also 
cell death. Recently, many abnormally expressed lncRNAs 
have been detected in ischemic stroke patients or animal 
models of ischemia using modern technologies, including 
deep sequencing, RNA-sequencing, and microarrays. Using 
RNA sequencing (RNA-seq) technology, Zhang et al. (2021) 
profiled long lncRNA expressional signatures in primary 
brain microvascular endothelial cells after oxygen-glucose 
deprivation, an in vitro mimic of ischemic stroke conditions. 
These authors showed that the most highly upregulated 
lncRNAs were Snhg12, Malat1, and lnc-OGD 1006, whereas 
the most highly down-regulated lncRNAs were 281008D09Rik, 
Peg13, and lnc-OGD 3916. 
To date, lncRNAs have emerged as an essential mediator 
of some neurological diseases, and clarifying their roles in 
cerebral ischemic injury may provide novel targets for the 
treatment of ischemic stroke. Chen et al. (2021) showed 
how silencing the lncRNA-XLOC_035088 in middle cerebral 
artery occlusion (MCAO)-induced rats reduced brain infarct 
size, and improved neurological function through inhibiting 
NOTCH1 following depression of presenilin 2. Hu et al. (2020) 
performed a study involving mice with cerebral ischemia. They 
concluded that downregulation of DLX6-AS1 reduced acute 
injury and ameliorated long-term neurological impairments. 
These authors also showed that silencing of DLX6-AS1 reduced 
neuronal apoptosis in vivo and in vitro. 
It is well known that acute cerebral ischemia may lead to 
severe brain injury caused by uncontrolled reperfusion. Ni et 
al. (2020) investigated the role of lncRNA nuclear enriched 
abundant transcript 1 (NEAT1) and demonstrated NEAT1 is an 
essential modulator of macrophages, particularly microglia 
(Delrio Ortega cells) through the regulation of AKT/STAT3 
pathway. Ni et al. (2020) showed that the expression of NEAT1 
was significantly upregulated in patients with ischemic stroke, 
and knockdown of the lncRNA NEAT1 reduced apoptosis and 
increased neuronal viability. Additionally, the lncRNA NEAT1 
may inhibit microglial polarization towards the M1 phenotype 
to reduce the activity of the AKT/STAT3 pathway. 
In a recent study, Lu et al. (2020) investigated the role of 
FOXD3-AS1 in cerebral ischemia/reperfusion injury and 
demonstrated that FOXD3-AS1 knockdown promoted the 
inhibitory impact of miR-765 on the expression of BCL2L13 
and the apoptosis, leading to attenuated neurological 
dysfunction and brain damages. 
In a comprehensive review, Wolska et al. (2020) mentioned 
the potential of early treatment with lncRNA as CC2dat and 
AK038897 and the potential benefits of modulating some 
lncRNAs as GAS5, N1LR and Rian. These can reduce the 
severity of neurological impairment after ischemic stroke and 
should be further investigated in preclinical research. 
The endothelial dysfunction and the alteration of the brain-
blood barrier are essential steps for the beginning of ischemic 
damage (Di Raimondo et al., 2013; Tuttolomondo et al., 2015; 
Petta et al., 2017; Tuttolomondo et al., 2020). In this field, 
functional importance and molecular regulatory mechanisms 
of lncRNAs in the endothelium following ischemic stroke 
are still unclear. Identification of new lncRNA transcripts will 
provide a novel window of opportunity to study RNA-directed 
epigenetic regulators in cerebral endothelial biology, and 
their essential role in stroke-induced vascular endothelium-
dependent cerebrovascular pathologies, as well as likely reveal 
novel targets for a promising translational future of lncRNA-
based diagnostics and therapeutics in ischemic stroke. 
miRNAs are small sequences of non-coding RNAs (ncRNAs; 
from 18 to 22 nucleotides) that bind specific regions of 
messenger RNAs regulating their expression and represent 
one of the subtler mechanisms of regulation of the gene 
expression (Correia de Sousa et al., 2019). miRNAs have 
a crucial function in a significant number of cellular and 
molecular pathways. Substantial evidence showed that 
following stroke, miRNAs would affect various physiological 
and pathological mechanisms, such as neurogenesis, 
hematopoiesis, proliferation, metabolism, immunity cells 
activation or depression (Jolana and Kamil, 2017; Mirzaei et 
al., 2018). Several studies have shown that miRNAs can be 
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Table 1 ｜ Principal non-coding RNA and their functions on the regulation of neuroinflammation
ncRNA Principal functions References
Long XLOC_035088 The silencing reduced brain infarct size and improved neurological function. Chen et al. (2021)
Non-coding RNAs DLX6-AS1 The silencing reduced acute injury, ameliorated long-term neurological impairments, and reduced 
neuronal apoptosis in vivo and in vitro.
Hu et al. (2020)
NEAT1 Regulation of AKT/STAT3 pathway. Silencing of NEAT1 reduced apoptosis and increased neuronal 
viability. 
Ni et al., (2020)
FOXD3-AS1 The silencing attenuated neurological dysfunction and brain damages. Lu et al., (2020)
Micro-RNAs miR-155 Targeting factors such as SOCS1, SHIP1, C/EBP-β and IL13Rα1, contributes to the induction of 
neuroinflammation.
Cardoso et al., (2012); 
Wang et al., (2020) 
miR-125b Astrogliosis increases the expression of glial cell markers glial fibrillary acidic protein (GFAP) and 
vimentin.
Pogue et al. (2010)
miR-146a Regulates inflammation negatively, promoting M2 mononuclear phagocytes. Wu et al., (2015); 
Huang et al., (2016)
miR-21 Exerts its anti-inflammatory action by targeting PDCD4 leading to downregulation of NF-κB and 
induction of the anti-inflammatory cytokine IL-10. Decreases TNF-α secretion by macrophages.
Sheedy et al., (2010); 
Wang et al. (2015)
miR-124 Anti-inflammatory functions, regulation of neuronal differentiation, monocyte polarization towards 
an M2 phenotype. Increased expression of miR-124, in microglial cells, reduces inflammation 
through downregulation of TNF-α and MHC-II and reduces the production of reactive oxygen 
species (ROS). 
Makeyev et al., (2007); 
Veremeyko et al., 
(2013); Louw et al., 
2016
let-7 miRNAs Promotes the polarization of macrophages and microglial cells towards the anti-inflammatory 
M2 phenotype. Serves as a damage-associated molecular pattern for TLR7 and promotes the 
activation of microglia and macrophages.
Cho et al., (2015); 
Lehmann et al., (2012)
AKT/STAT3: Protein kinase B/signal transducer and activator of transcription 3; C/EBP-β: CCAAT enhancer binding protein beta; DLX6-AS1: DLX6 antisense RNA 1; 
FOXD3-AS1: FOXD3 Antisense RNA 1; IL-10: interleukin 10; IL13Rα1: interleukin 13 receptor alpha 1; MHC-II: major histocompatibility complex 2; NEAT1: 
nuclear paraspeckle assembly transcript 1; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; PDCD4: programmed cell death 4; SHIP1: SH-2 
containing inositol 5' polyphosphatase 1; SOCS1: suppressor of cytokine signaling 1; TLR7: toll-like receptor 7; TNF-α: tumor necrosis factor alpha. 
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used as prognostic, diagnostic, and therapeutic biomarkers of 
stroke (Wang et al., 2017). 
It has been well documented that the inflammatory processes 
underlying neuroinflammation may be promoted or 
suppressed by different miRNAs. 
miR-155 is a central pro-inflammatory mediator of the 
central nervous system (CNS) which is induced within 
macrophages and microglia in response to nuclear factor-
κB (NF-κB) dependent toll-like receptor (TLR) signalling, and 
targeting factors such as SOCS1, SHIP1, C/EBP-β and IL13Rα1, 
contributes to the induction of neuroinflammation (Wang et 
al., 2010; Cardoso et al., 2012). Pogue et al. (2010) showed 
that miR-125b played a role in the process of astrogliosis, 
decreasing the expression of CDKN2A, a negative regulator of 
cell growth that inhibits the growth of astrocytes by binding to 
the 3′UTR of cyclin-dependent kinase inhibitor 2A (CDKN2A). 
The authors also showed a strong positive correlation 
between miRNA-125b abundance and the glial cell markers 
glial fibrillary acidic protein and vimentin. 
Contrary to other miRNAs, miR-146a regulates inflammation 
negatively. miR-146a is expressed in different cytotypes 
such as neurons, microglia and astrocytes, and it is induced 
by TLR signaling (Cui et al., 2010). miR-146a acts as a 
negative feedback regulator of NF-κB signalling by targeting 
components of the MyD88 signalling complex, including 
IRAK1 and TRAF6, it targets other pro-inflammatory mediators 
including STAT-1, IRF-5 and CFH (Wu et al., 2015). miR-
146a performs a function in the intracerebral macrophage 
polarization through the Notch1 pathway, promoting M2 
mononuclear phagocytes which play functions in tissue repair 
processes through phagocytosis and immune tolerance (Huang 
et al., 2016). 
miR-21 is another highly expressed miRNA in a variety of 
cytotypes such as active immune cells (macrophages, mast 
cells, neutrophils and T-cells) (Sheedy, 2015) and various cell 
types of the CNS including microglia, astrocytes, neurons and 
oligodendrocytes (Zhang et al., 2012; Li et al., 2018). miR-21, 
induced by TLR signalling through MyD88 and NF-κB, exerts 
its anti-inflammatory action by targeting PDCD4, leading to 
downregulation of NF-κB and expression of anti-inflammatory 
cytokine IL-10 (Sheedy et al., 2010). Additionally, miR-21 
decreases tumor necrosis factor-alpha (TNF-α) secretion by 
macrophages (Wang et al., 2012).
miR-124 is  another brain-specif ic  miRNA with anti-
inflammatory functions that is involved in the regulation 
of neuronal differentiation (Makeyev et al., 2007) and the 
monocyte polarization towards an M2 phenotype. The 
expression of miR-124 may be induced in monocytes and 
macrophages in response to the Th2 cytokines IL-4 and IL-
10 (Veremeyko et al., 2013). Increased expression of miR-
124, in microglial cells, reduces inflammation through 
downregulation of TNF-α and MHC-II and reduces the 
production of reactive oxygen species (Louw et al., 2016). 
miR-124 is a crucial negative regulator of neuroinflammation 
by reducing inflammatory mediators and restricting microglia 
to an inactive state.
The let-7 miRNAs, a family of evolutionarily conserved 
miRNA, serve as essential modulators of neuroinflammatory 
processes. Let-7 miRNAs, targeting the C/EBP-δ transcription 
factor, promote the polarization of macrophages and 
microglial cells towards the anti-inflammatory M2 phenotype 
(Cho et al., 2015). A peculiar action carried out by let-
7 miRNAs is to serve as a damage-associated molecular 
pattern for TLR7 and to promote activation of microglia and 
macrophages (Lehmann et al., 2012).
As to inflammatory cytokines, miRNAs could also act by 
modulating their expression in the ischemic stroke brain 
tissues. An explicative example is represented by interferon 
β, an anti-inflammatory cytokine that can prevent the neuron 
against ischemic injury. Some miRNAs such as miR-34a, let-
7b, miR-26a, miR-145, have their targeting site in the 3′UTR of 
interferon β and they regulate the expression of interferon β to 
influence the outcome of ischemic stroke (Wanve et al., 2019).
Mesenchymal Stem/Stromal Cells
Today, a promising field of research is represented by the 
utilization of mesenchymal stem/stromal cells (MSCs). MSCs 
are a subset of cells with a robust immunomodulatory 
function that can be readily obtainable and easily expandable 
in vitro. These cells can be reached from many different 
tissues (peripheral blood, bone marrow, adipose tissue, 
umbilical cord blood), and these cells are being studied for 
several pathological conditions because of their ability to 
differentiate into various cell types, to migrate to multiple 
tissues, and to exert potent immunomodulatory functions 
(Hass et al., 2011). MSCs can influence target cell function 
through the secretion of large amounts of exosomes. MSC-
derived exosomes (Msc-exosomes) expressing miRNA have 
been used in the treatment of various diseases such as stroke, 
which can be associated with the implementation of processes 
of neurogenesis, angiogenesis, and neuroprotection (Musiał-
Wysocka et al., 2019). 
Voltage-Gated Potassium Channel KV1.3 Role in 
Microglia-Mediated Neuroinflammation
The voltage-gated potassium channels KV1.3 were initially 
described as a target for treating T-cell mediated immune 
diseases such as multiple sclerosis and psoriasis (Beeton et 
al., 2006; Tarcha et al., 2012; Chandy and Norton, 2017). 
Recently, KV1.3 blockers were studied as a pharmacological 
target to reduce neuroinflammation by modulating microglia 
activation. In both mouse and rat models of ischemic stroke, 
KV1.3 blockers showed a potential to reduce ischemic area 
and improve neurological damage (Ma et al., 2020). 
KV1.3 blockers could be useful, as shown in mouse models, in 
Alzheimer’s disease, white matter pathology after traumatic 
brain injury and radiation-induced brain damage. KV1.3 
blockers are overexpressed in mRNA, and protein levels in 
lipopolysaccharide stimulated microglia, which simulate 
neuroinflammation and amyloid-β stimulated microglia, that 
are used for simulating Alzheimer’s disease microenvironment. 
In a recent study, Nguyen et al. (2017) showed the effects of 
KV1.3 blockers (microglia inhibitor minocycline on differentially 
polarized neonatal mouse microglia) reduced expression and 
production of the pro-inflammatory cytokines interleukin (IL)-
1β and TNF-α at 24 and 28 hours and prevented upregulation 
of the inflammation associated enzymes cyclooxygenase-2 
and inducible nitric oxide synthase more than KCa3.1. 
In another study, Sarkar et al. (2020) showed as both 
pharmacological KV1.3 inhibition with PAP-1 and genetic 
deletion of the channel resulted in reductions of IL-1β, IL-
6, IL-12 and TNF-α production and prevented NLRP3 protein 
upregulation at 24 hours after microglia stimulation. 
To date, Nguyen et al. (2017) reported that microglia cells 
express KV1.3 and that KV1.3 inhibition suppresses the 
functions of pro-inflammatory, neurotoxic microglia and 
might even shift microglia toward a more neuroprotective 
phenotype (M2). Further studies are needed to understand 
the importance of their role in ischemic stroke.
Adenosine 2B Receptor 
Adenosine is a nucleoside belonging to the purinergic system, 
involved in various physiological and pathological processes. In 
the CNS, adenosine derives from adenosine monophosphate 
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barrier, and in terms of other cell therapy related problems 
such as tumor formation and infarcts caused by vascular 
occlusion (Bang and Kim, 2019). 
Conclusions 
The data emerging from the literature continues to fuel hopes 
that these molecules can significantly improve the outcome 
of patients with ischemic stroke. A better understanding 
of the mechanisms that influence the “polarization” of the 
inflammatory response after the acute event seems to be the 
way to change the natural history of the disease. Nevertheless, 
it is probable that an increasing number of these molecules 
will progress and will eventually be developed to become an 
approved treatment for ischemic stroke in the coming years.
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